|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma.
|
31429760 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We developed humanized, second-generation CAR T cells against another B cell-specific marker, B cell activating factor receptor (BAFF-R), which demonstrated cytotoxicity against human lymphoma and acute lymphoblastic leukemia (ALL) lines.
|
31554741 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical studies investigating efficacy and safety of CAR-T in acute and chronic lymphocytic leukemia and lymphoma were identified by searching PubMed and EMBASE.
|
28762313 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The advent of chimeric antigen receptor T (CAR-T) and the burgeoning field of cellular therapy has revolutionized the treatment of relapsed/refractory leukemia and lymphoma.
|
31355491 |
2019 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapies have been approved for use in relapsed or refractory leukemia and lymphoma based on promising efficacy in clinical trials.
|
30500439 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive cellular therapies using chimeric antigen receptor T (CAR-T) cells have achieved remarkable clinical responses in B cell leukemia and lymphoma but the effect on solid tumors including lung cancer is limited.
|
30670085 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-engineered T (CAR-T)-cell therapy holds significant promise for the treatment of hematological malignancies, especially for B-cell leukemia and lymphoma.
|
31432594 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Several ongoing and upcoming clinical trials of CD30-directed CAR-T cells are expected to further enhance this approach to treat patients with relapsed and refractory CD30+ lymphomas.
|
30841880 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma.
|
30198955 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells have revolutionized the treatment of relapsed and refractory CD19-positive leukemia and lymphoma.
|
30680777 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.
|
30791947 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.
|
30300581 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma.
|
30443597 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.
|
29032736 |
2017 |